4.8 Article

Preparation and characterization of polymeric coatings with combined nitric oxide release and immobilized active heparin

Journal

BIOMATERIALS
Volume 26, Issue 33, Pages 6506-6517

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2005.04.046

Keywords

nitric oxide; heparin; diazeniumdiolates; blood compatible polymers; controlled released; anti-coagulant; anti-platelet activity

Funding

  1. NIBIB NIH HHS [EB-00783] Funding Source: Medline
  2. NICHD NIH HHS [HD-015434] Funding Source: Medline

Ask authors/readers for more resources

A new dual acting polymeric coating is described that combines nitric oxide (NO) release with surface-bound active heparin, with the aim of mimicking the nonthrombogenic properties of the endothelial cell (EC) layer that lines the inner wall of healthy blood vessels. A trilayer membrane configuration is employed to create the proposed blood compatible coating. A given polymeric substrate (e.g., the outer surface of a catheter sleeve, etc.) is first coated with a dense polymer layer, followed by a plasticized poly(vinyl chloride) (PVC) or polyurethane (PU) layer doped with a lipophilic N-diazeniumdiolate its the NO donor species. Finally, an outer aminated polymer layer is applied. Porcine heparin is then covalently linked to the Outer layer via formation of amide bonds. The surface-bound heparin is shown to possess anti-coagulant activity in the range of 4.80 6.39nill-1/cm(2) as determined by a chromogenic anti-Factor Xa assay. Further, the surface NO flux from the underlying polymer layer containing the diazeniumdiolate species can be controlled and maintained at various levels (from 0.5 to 60 x 10 (10)mol cm (2)min (1)) for at least 24 It and up to I week (depending on the flux level desired) by changing the chemical/polymer composition of the NO release layer. The proposed polymeric coatings are capable of functioning by two complementary anti-thrombotic mechanisms, one based on the potent antiplatelet activity of NO, and the other the result of the ability of immobilized heparin to inhibit Factor Xa and thrombin (Factor IIa). Thus, the proposed polymeric coatings are expected to exhibit greatly enhanced thromboresistivity compared to polymers that utilize either immobilized heparin or NO release alone. (c) 2005 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available